Procalcitonin/albumin ratio as a novel biomarker for predicting mortality in COVID-19

Basit Öğe Kaydı
dc.authorid0000-0002-4547-6489en_US
dc.authorid0000-0002-7957-7173en_US
dc.authorid0000-0003-3857-685Xen_US
dc.authorid0000-0003-3637-4074en_US
dc.authorid0000-0002-6875-9115en_US
dc.contributor.authorErgenç, Hasan
dc.contributor.authorErgenç, Zeynep
dc.contributor.authorÖztürk, Cemal Koray
dc.contributor.authorGözdaş, Hasan Tahsin
dc.contributor.authorOcak, Özlem Karaca
dc.contributor.authorİnce, Özgür
dc.date.accessioned2023-08-03T07:24:24Z
dc.date.available2023-08-03T07:24:24Z
dc.date.issued2022en_US
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: Coronavirus disease 2019 (COVID-19) first appeared in China in December 2019, and has become a global pandemic. Because the clinical progression of the disease is highly variable, better prediction of prognosis and mortality is important. In the present study, we investigated the role of procalcitonin/albumin ratio (PAR) as a new biomarker in predicting mortality in patients with COVID-19 infection. Methods: In this study, patients with COVID-19 diagnosis were enrolled from Sakarya Yenikent State Hospital and Ayancik State Hospital between 09.11.2020 and 04.05.2021. The demographic characteristics, biochemical and hematological parameters such as age, gender, length of hospital stay, and comorbidities of the patients were collected retrospectively from medical records. Results: Of the 105 patients, 51 were mild and 54 were critically ill. Between mild and critical cases, age, lymphocyte count, red cell distribution width, neutrophile count, mean corpuscular volume (MCV), monocvte count, albumin, C-reactive protein, ferritin, procalcitonin, D-dimer, and PAR were statistically different (p<0.001 for all). All patients in the critical group and only 2% of the mild group died. PAR showed the largest area under the curve (0.949) for the prediction of mortality (p<0.001). Conclusion: We report that PAR, a simple, cheap, and easily accessible biomarker, can be used to predict the prognosis in patients with COVID-19 infection.en_US
dc.identifier.citationErgenç, H., Ergenç, Z., Öztürk, C. K., Gozdas, H. T., Ocak, Ö. K., & İnce, Ö. (2022). Procalcitonin/albumin ratio as a novel biomarker for predicting mortality in COVID-19. J Pioneering Med Sci, 11(1), 3-7.en_US
dc.identifier.endpage7en_US
dc.identifier.issn2309-7981
dc.identifier.issue1en_US
dc.identifier.startpage3en_US
dc.identifier.urihttps://www.webofscience.com/wos/woscc/full-record/WOS:000797823300002
dc.identifier.urihttps://hdl.handle.net/20.500.12491/11422
dc.identifier.volume11en_US
dc.identifier.wosWOS:000797823300002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.institutionauthorGözdaş, Hasan Tahsin
dc.language.isoenen_US
dc.publisherJPMS Publicationen_US
dc.relation.ispartofJournal of Pioneering Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCOVID-19en_US
dc.subjectProcalcitonin/Albumin Ratioen_US
dc.subjectMortalityen_US
dc.subjectPrognosisen_US
dc.subjectSerum Procalcitoninen_US
dc.subjectLaboratory Findingsen_US
dc.titleProcalcitonin/albumin ratio as a novel biomarker for predicting mortality in COVID-19en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
hasan-ergenc.pdf
Boyut:
263.36 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu